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Women diagnosed with a first breast cancer before the age of 45 years have a greater than 5.0-fold risk of developing a second
primary contralateral breast cancer (CBC) than women in the general population have of developing a first breast cancer. Identifying
epidemiologic or molecular factors that influence CBC risk could aid in the development of new strategies for the management of
these patients. A total of 1285 participants in two case–control studies conducted in Seattle, Washington, who were 21–44 years of
age when diagnosed with a first invasive breast carcinoma from 1983 to 1992, were followed through December 2001. Of them, 77
were diagnosed with CBC and 907 tumour tissues from first cancers were analysed. Women with body mass indices (BMIs)
X30kgm
 2 had a 2.6-fold greater risk (95% CI: 1.1–5.9) of CBC compared to women with BMIs p19.9kgm
 2. Women whose
first tumour was c-erbB-2 positive had a 1.7-fold (95% CI: 1.0–3.0) excess CBC risk. Body mass index and c-erbB-2 expression may
be risk factors for CBC in young women. Further observational studies are needed to confirm these findings and to evaluate whether
testing for c-erbB-2 in this population may help identify those at high risk for CBC.
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The strongest identified risk factor for second primary contral-
ateral breast cancer (CBC) is the age at diagnosis of a woman’s first
primary breast cancer (Chen et al, 1999). The younger a woman is
diagnosed with an initial breast cancer, the greater her risk is of
developing CBC. In a cohort study of 41109 US women diagnosed
with a first breast cancer, women diagnosed before the age of 45
years had a 5.4-fold greater risk of CBC than expected. Women of
45–54 and 55þ years of age had 3.4- and 1.3-fold greater risks of
CBC, respectively (Harvey and Brinton, 1985). Smaller studies
from England (Prior and Waterhouse, 1978), Sweden (Adami et al,
1985), Japan (Murakami et al, 1987), Germany (Brenner et al,
1993), and Slovenia (Volk and Pompe-Kirn, 1997) have reported
similar results, finding that women o45 or o50 years of age have
3.0–9.9-fold greater risks of CBC than expected.
A family history of breast cancer and having a first breast
tumour with a lobular histology have also been shown to increase
CBC risk, while treatment of a first primary breast cancer with
chemotherapy or tamoxifen has each been shown to decrease CBC
risk (Chen et al, 1999). Although numerous studies have evaluated
these and other risk factors for CBC, few have had sufficient power
to evaluate epidemiologic or molecular risk factors among women
diagnosed with a first breast cancer at a young age. Thus, little is
known about what factors predispose young women diagnosed
with a first breast cancer to develop CBC. To evaluate risk factors
for CBC among women diagnosed with a first breast cancer at age
younger than 45 years, we followed 1285 participants in a
population-based case–control study, who were diagnosed with
breast carcinoma from 1983 through 1992 in the Seattle-Puget
Sound area of western Washington State for the occurrence of CBC.
METHODS
Case ascertainment and interviews
The 1488 breast carcinoma patients eligible for this study were
women who had previously been interviewed in two population-
based case–control studies. Women with in situ disease alone
(n¼203) were excluded from our study, and the remaining 1285
women with invasive breast cancer formed our cohort. Both
methods of case–control studies were essentially the same and
have been described previously (Daling et al, 1994; Brinton et al,
1995). The Cancer Surveillance System (CSS), a population-based
cancer registry that is part of the Surveillance, Epidemiology, and
End Results (SEER) Program of the National Cancer Institute, was
used by both studies to identify women diagnosed with breast
cancer who resided in King, Pierce, or Snohomish counties in
western Washington state. The first study ascertained all incident
cases of first in situ or invasive primary breast cancers among non-
Hispanic white women who were diagnosed from 1 January 1983
through 30 April 1990 at 45 years of age or younger and who were
born after 1944. Interviews were completed on 845 cases (83.3% of
eligible cases). The second study ascertained all incident first in
situ and invasive primary breast cancer cases of any race who were
diagnosed from 1 May 1990 through 31 December 1992 at age less
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ythan 45 years. Interviews were completed on 643 (83.9%) of all
eligible cases.
Participants in both studies were interviewed in their homes by
a trained interviewer. Respondents were asked about their
reproductive history, family history of breast cancer, and their
body size history. Weight 1 year prior to diagnosis was used to
determine body mass index (BMI) for this study. In our analyses,
BMI was grouped using Bray’s criteria (Bray, 1987) (where women
with a BMI p19.9kgm
 2 are considered underweight, 20.0–
24.9kgm
 2 as normal weight, 25.0–29.9kgm
 2 as overweight, and
X30.0kgm
 2 as obese) and into quartiles. Information on ever
use of treatments for the subjects’ first breast cancer, including
chemotherapy, radiation, and tamoxifen, was subsequently ob-
tained from three sources: (1) medical record abstractions, (2)
telephone and written contacts with subjects or their proxies, and
(3) CSS. Informed consent was obtained from all subjects prior to
participation.
Follow-up for CBC
The source of information on occurrence of CBC in the cohort was
CSS, which follows all cancer cases for vital status and the
diagnosis of subsequent primary cancers. The length of follow-up
time for cohort members was measured as the time from 6 months
after the diagnosis of their first breast cancer to diagnosis of CBC;
date of last follow-up; death; or the end of the study period
(December 2001), whichever occurred first. Women were con-
sidered to have developed CBC if their second breast tumour was:
(1) diagnosed greater than 6 months after their first breast cancer
was diagnosed; (2) was diagnosed in the opposite breast; and (3)
was invasive. All participants had a follow-up time of 6 months or
greater. The registry annually contacts the hospital tumour
registrar for information on the disease status and vital status of
each patient. The tumour registrar then contacts the physician
following each patient for an updated determination of vital status.
If there is no physician who has had sufficiently recent contact
with the patient, then the registrar sends a letter to the patient.
This follow-up for both disease status and vital status is performed
for cases, regardless of whether or not they currently reside in the
CSS catchment area. In addition, passive surveillance through
routine computer linkage of patients with Washington State death
certificates, the National Death Index, and Health Care Finance
Administration tapes is conducted. The status of greater than 85%
of the cohort was known within 2 years of December 2001.
Tissue collection, pathology review, and testing for
molecular markers
Data on tumour stage, histology, and size were obtained from CSS.
Tumour specimens were requested from hospital and commercial
pathology laboratories. We were unable to obtain permission to
request tumour tissue from 4.1% of the women. In addition, 25.3%
of the tumour blocks were not available or had been discarded by
the pathology laboratories.
Tumour tissue sufficient for immunoperoxidase assays was
available for 907 (70.6%) of the study participants. The study
pathologist (Peggy L Porter, MD) conducted a complete histo-
pathologic review for all the tumours collected. The CBC status and
clinical and personal characteristics of the women were unknown
at the time of review. Expression of oestrogen receptor (ER),
progesterone receptor (PR), p53 tumour suppression gene protein,
Ki-67 proliferation-related antigen, c-erbB-2 oncogene protein,
apoptosis regulatory protein bcl-2, and cell cycle proteins cyclin E
and p27 were evaluated on sections from a single tumour block as
described previously (Porter et al, 1997, 1999).
Antibodies were scored using a subjective interpretation of
staining intensity and/or the percentage of tumour cells
positive. Categories of intensity and/or percent cells positive were
collapsed into positive/high or negative/low categories as follows:
for ER and PR, any nuclear staining was considered positive; the
percentage of Ki-67 positive tumour cells was averaged over four
high-powered fields and converted to quartiles; the nuclear
staining of 410% tumour cells for p53 was considered positive;
a distinct membranous staining pattern of 1–3þ was considered
positive for c-erbB-2. The antibody staining for c-erbB-2 was
carried out using the AO485 antibody from DAKO and was
initiated prior to the acceptance of the DAKO’s Herceptest kit as
the FDA-approved technique for the evaluation of c-erbB-2
expression. The clinical use of this marker to determine therapy
was not the objective of this study and as such, we assigned
Table 1 Characteristics of a cohort of 1285 women diagnosed with a first primary breast cancer between 1 January 1983 and 31 December 1992
Entire cohort (n¼1285) Cohort with tumour marker data (n¼907)
Characteristics Average % Missing data (%) Average % Missing data (%)
Age (years) (s.d.) 37.7 (4.3) 0.0 38.0 (4.2) 0.0
Follow-up (years) (s.d.) 9.0 (3.8) 0.0 8.5 (3.5) 0.0
Age at first birth (years) (s.d.) 24.3 (5.1) 0.3 24.7 (5.2) 0.1
Body mass index (kgm
 2) (s.d.) 23.9 (5.0) 1.4 24.1 (5.0) 1.7
Family history (%) 1.8 1.8
None 63.2 64.1
First-degree relative affected 15.6 15.2
Second-degree relative affected 21.2 20.8
AJCC stage (%) 1.9 0.6
I 37.5 37.5
II 51.0 51.3
III 8.7 9.0
IV 2.7 2.2
Lobular histology (%) 3.4 0.0 3.6 0.0
Tumour size (cm) (s.d.) 1.7 (3.4) 20.7 1.5 (3.3) 0.0
Breast cancer treatments received (%)
Chemotherapy 71.5 0.2 74.4 0.0
Radiation 56.8 0.2 56.7 0.1
Tamoxifen 38.3 8.7 41.5 4.5
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over that of normal breast epithelium to the positive category. The
intensity of bcl-2 stains was categorised as negative, low,
intermediate, and high. Expression of cyclin E and p27 was scored
as a value from 1 (negative) to 7 (highest intensity). Low intensity
included all values of 1–4 and high intensity included values from
5t o7 .
Bivariate flow cytometric analysis of DNA content and S-phase
fraction was completed for 694 (59%) of the tumours, as described
previously (Glogovac et al, 1996).
Table 2 Risk of CBC by patient characteristics at the time of first cancer diagnosis
Number of
Subjects at risk P-years Number of CBC cases
Patient Characteristics n¼1285 at risk n¼77 HR 95% CI
Age at diagnosis (years)
p29 65 592 7 2.8 1.1, 6.9
30–34 201 1848 17 2.1 1.1, 4.4
35–39 477 4375 36 1.9 1.1, 3.5
40+ 515 4444 17 1.0 Ref.
Age at menarche (years)
8–12 665 6020 35 1.0 Ref.
13–15 550 4865 40 1.5 0.9, 2.3
16+ 43 374 2 0.9 0.2, 3.7
Gravidity
Never pregnant 204 1857 16 1.0 Ref.
Ever pregnant 1,053 9391 61 0.9 0.5, 1.6
Age at first live birth (years)
o20 177 1626 8 1.0 Ref.
20–29 590 5272 39 1.5 0.7, 3.2
30+ 161 1321 9 1.5 0.6, 4.0
Number of live births
None 331 3041 21 1.0 Ref.
1–3 856 7566 50 1.2 0.7, 2.0
4+ 70 641 6 1.7 0.7, 4.4
Oral contraceptive use (years)
None 282 2451 16 1.0 Ref.
o10 807 7319 48 1.0 0.6, 1.8
10+ 169 1489 13 1.3 0.6, 2.7
BMI, using Bray’s criteria (kgm
 2)
p19.9 212 2104 11 1.0 Ref.
20.0–24.9 669 6077 43 1.6 0.8, 3.1
25.0–29.9 205 1743 11 1.5 0.6, 3.6
30.0+ 154 1200 12 2.6 1.1, 5.9
BMI, quartiles (kgm
 2)
p20.6 309 3008 16 1.0 Ref.
20.7–22.4 312 2911 18 1.2 0.6, 2.4
22.5–25.8 311 2703 26 2.1 1.1, 3.9
25.9+ 316 2550 17 1.6 0.8, 3.2
Weight, quartiles (lb)
p123 331 3178 14 1.0 Ref.
124–135 320 3003 18 1.5 0.7, 3.0
136–155 311 2656 27 2.8 1.4, 5.3
156+ 294 2405 18 2.2 1.1, 4.4
Average number of drinks per week
None/o1 507 4421 31 1.0 Ref.
1–3 297 2689 17 0.9 0.5, 1.6
3+ 452 4134 29 0.9 0.5, 1.5
Family history of breast cancer
None 778 6838 40 1.0 Ref.
First degree 193 1850 17 1.5 0.9, 2.7
Second degree 264 2395 18 1.3 0.8, 2.3
HRs for age at diagnosis are adjusted for year at diagnosis, AJCC stage, chemotherapy, and the study that the subjects
participated in. All other HRs are adjusted for age and year at diagnosis, AJCC stage, chemotherapy, and the study that the
subjects participated in. P-years¼patient-years; HR¼hazard ratio; AJCC¼American Joint Committee on cancer;
Ref.¼reference.
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Associations between different epidemiologic and molecular risk
factors for CBC were estimated using the Cox proportional hazard
model (Cox, 1972). Using Stata 7.0 (College Station, TX for
Windows (Stata Corporation, Chicago, IL, USA) statistical soft-
ware, Cox regression was performed to compute hazard ratios and
95% confidence intervals (CI) and to evaluate the effects of
confounding and modifying factors. Systematic evaluation for
confounding by other potential confounders, including stage,
histologic type, and other treatments, was performed. All analyses
were adjusted for age and year at diagnosis, American Joint
Committee on Cancer (AJCC) stage, chemotherapy, and the
original study in which the subjects had participated.
RESULTS
The mean age at diagnosis of first primary breast cancer for the
entire cohort was 37. 7 years, and the mean follow-up time was 9.0
years (range: 0.5–18.1 years) (Table 1). The average age at first live
birth was 24.3 years and the mean BMI was 23.9kgm
 2.
Additionally, 15.6% of the cohort had a first-degree family history
of breast cancer and 21.2% had a second-degree family history.
The majority of women were diagnosed with either stage I or II
breast cancer, the mean tumour size was 1.7cm, and only 3.4% of
the women had lobular carcinoma. In all, 71.5% of the cohort had
their first breast cancer treated with chemotherapy, 56.8% received
radiation therapy, and 38.3% ever used tamoxifen. In general, the
cohort of women, whose tumour tissue was evaluated for
molecular markers, did not differ from the entire cohort with
respect to these characteristics.
Multivariable-adjusted estimates of risk for CBC in relation to
various patient characteristics are presented in Table 2. Women
diagnosed with their first breast cancer when they were p29, 30–
34, and 35–39 years of age had 2.8 (95% CI: 1.1–6.9), 2.1 (95% CI:
1.1–4.4), and 1.9-fold (95% CI: 1.1–3.5) greater risks of CBC
compared to women diagnosed at 40–44 years of age, respectively.
Women with first live births after the age of 20 years and with a
greater number of live births also appeared to have greater risks of
CBC, but these increases were within the limits of chance. Using
Bray’s criteria (Bray, 1987), women who were obese (BMI
X30.0kgm
 2) when diagnosed with their first breast cancer also
had an increased risk of CBC compared to women with a BMI
p19.9kgm
 2. When assessed as quartiles, women in the upper
two quartiles of BMI had a greater risk of CBC compared to
women in the lowest quartile (although the increase in risk
for those in the highest quartile was within the limits of chance).
With respect to weight, women who were in the upper two
quartiles of weight had a greater risk of CBC compared to women
in the lowest quartile. Alcohol use was not associated with an
increased risk of CBC. Finally, a first-degree family history
increased CBC risk 1.5-fold, although this increase was within
the limits of chance.
Neither stage, histology, nor tumour size of the first tumour
appeared to alter CBC risk (Table 3). With respect to the tumour
markers expressed by these first tumours, women whose first
tumour was c-erbB-2 positive had a 1.7-fold (95% CI: 1.0–3.0)
increased risk of CBC (Table 4). However, other markers,
including ER, PR, bcl-2, cyclin E, Ki-67, p27, p53, and S phase
were not associated with CBC risk.
DISCUSSION
Although numerous studies have assessed risk factors for CBC, few
have assessed CBC risk factors among women diagnosed with their
first breast cancer before the age of 45 years. Since the risk of CBC
increases the younger a woman is diagnosed with a first breast
cancer, as this and other studies suggest, identification of factors
that contributes to their risk is important.
In this study, we observed that both obesity (defined as a BMI
X30.0kgm
 2) and a total body weight in the upper two quartiles
at the time women were diagnosed with their first breast were
associated with increases in CBC risk. The relation of BMI to breast
cancer risk and mortality is complex. A high BMI is protective of
premenopausal breast cancer, but increases a woman’s risk of
postmenopausal breast cancer. However, BMI is also positively
correlated with risk of mortality among both premenopausal
(Greenberg et al, 1985; Holmberg et al, 1994; Lethaby et al, 1996;
Daling et al, 2001) and postmenopausal (Goodwin and Boyd, 1990)
women with breast cancer. The relation between BMI and CBC risk
is less clear, although one study reports that CBC risk increases as
BMI increases (Storm et al, 1992) and others report that BMI does
not influence CBC risk (Hislop et al, 1984; Horn and Thompson,
1988; Bernstein et al, 1992). However, none of these studies have
assessed women diagnosed with their first breast cancer before the
age of 45 years separately. While our finding is novel, it needs to be
Table 3 Risk of CBC by tumour characteristics of first cancer diagnosis
Number of
Subjects at risk P-years Number of CBC cases
Tumour Characteristics n¼1285 at risk n¼77 HR 95% CI
AJCC stage
I 473 4587 31 1.0 Ref.
II 641 5702 42 1.0 0.6, 1.6
III 110 842 3 0.5 0.1, 1.7
IV 34 128 1 1.1 0.1, 8.1
Histology
Ductal 922 8370 59 1.0 Ref.
Medullary 44 395 2 0.9 0.2, 3.6
Lobular 52 492 3 0.7 0.2, 2.3
Other 265 2248 13 0.9 0.5, 1.6
Size (cm)
p2.0 653 6167 39 1.0 Ref.
42.0–5.0 498 4271 34 1.2 0.7, 1.9
45.0 102 803 4 0.7 0.3, 2.1
HRs adjusted for age and year at diagnosis, AJCC stage, chemotherapy, and the study subjects participated in. P-
years¼patient-years; HR¼hazard ratio; AJCC¼American Joint Committee on cancer; Ref.¼reference.
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mechanisms underlying an association between body weight and
CBC.
There are limitations of our data concerning body weight and
BMI as the data on all patient characteristics were based on self-
reports. This may have been a particular problem for our
analyses of weight and BMI (calculated from self-reported
heights and weights), since participants in research studies may
underestimate their weight. This issue has been addressed to some
extent since women in the second case–control study who formed
our cohort were weighed and measured at the time of their
interview. It has been shown that the correlation between self-
reported weight 1 year before diagnosis and weight measured at
the interview for these women was R¼0.89 (Daling et al, 2001),
suggesting that self-reported weight is reliable among women in
our study.
With respect to molecular markers that are related to CBC risk,
we found that expression of c-erbB-2 was associated with an
increased CBC risk in our cohort. Given that c-erbB-2 is a potent
oncogene and a strong predictor of prognosis, this finding is not
surprising, although it needs to be verified by others. While we did
not find that any of the other markers we evaluated significantly
altered CBC risk, this study was limited by a relatively small
number of CBC cases and thus may have lacked sufficient power to
detect these associations. Furthermore, this study is largely
hypothesis generating and therefore these associations need to
be viewed tentatively. Additional insight into the molecular
aetiology of CBC is needed and could be gained by the assessment
of these and other markers in the contralateral tumours themselves
and by comparing them to those expressed by first primary breast
tumours.
In summary, we present the first data from a large group of
young women with breast cancer and find that high BMI at the
time of a first breast cancer diagnosis and c-erbB-2 expression by
this tumour, both appear to be important risk factors for CBC. If
these associations are borne out in future studies, the subgroups of
women who either have a high BMI or whose first tumours
overexpress c-erbB-2 may warrant closer screening for CBC.
Additionally, it will be important to establish whether interven-
tions such as treatment with c-erbB-2-targeted therapies, such as
trastuzumab, after diagnosis with breast cancer alter the incidence
of CBC in young women.
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